H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $47 from $39 and keeps a Buy rating on the shares after the company announced FDA approval of Optune Pax for the treatment of locally advanced pancreatic cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure’s Optune Pax approved by FDA to treat pancreatic cancer
- Novocure Wins FDA Approval for Optune Pax in Pancreatic Cancer
- Maintaining Buy on NovoCure: Viewing CMS Billing Revocation as a Temporary Administrative Setback with Limited Long-Term Impact
- NovoCure Faces CMS Billing Revocation, Revenue Impact Uncertain
- Novocure price target lowered to $39 from $42 at H.C. Wainwright